Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer.
Wu TC, Stube A, Felix C, Oseguera D, Romero T, Goldman J, Garon EB, Lee JM, Glaspy J, Lisberg AE, Rusthoven CG, Camidge DR, Siva S, Solomon B, Lee A, Tenn SE, Shaverdian N, Steinberg ML, Raldow AC, Lee P.
Wu TC, et al. Among authors: tenn se.
Int J Radiat Oncol Biol Phys. 2023 Sep 1;117(1):118-122. doi: 10.1016/j.ijrobp.2023.03.069. Epub 2023 Apr 5.
Int J Radiat Oncol Biol Phys. 2023.
PMID: 37023987
Clinical Trial.
No abstract available.